Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
US bypasses congressional review for military sales of $8.6bn to Middle East allies
- 2 گھنٹے قبل
Larry’s risky business
- 14 گھنٹے قبل
Is this ‘de-extinction’ project actually onto something?
- 14 گھنٹے قبل
Finance Minister vows investor-friendly policy environment
- 37 منٹ قبل
General Motors is adding Gemini to four million cars
- 14 گھنٹے قبل
ChatGPT downloads are slowing — and may cause problems for OpenAI’s IPO
- 14 گھنٹے قبل
Microsoft Office can now be controlled with Logitech’s MX Creative Console
- 5 گھنٹے قبل
Foreign Office terms social media post by British SRA as one-sided
- ایک گھنٹہ قبل
Ex Senator Mushtaq Ahmad released from Israeli custody: Dar
- 2 گھنٹے قبل
Microsoft is giving its Xbox employees an Xbox email address
- 5 گھنٹے قبل
Iranian proposal rejected by Trump would open strait before nuclear talks, Iran official says
- 3 گھنٹے قبل
What haunts America’s animal shelter workers
- 12 گھنٹے قبل
